Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK NICE To Pharma Firms: Up Your Game In Horizon Scanning

Executive Summary

Pharmaceutical companies must play a fuller part in planning for health technology appraisals by NICE, which has resource limitations and cannot do everything that companies might expect of it, a recent workshop in London heard.

Related Content

UK’s NICE Price Discounts ‘Pass Risk To Patients’
ABPI Exec Lauds Innovation And Access Provisions In New UK Voluntary Scheme
UK NICE Review Will Look At Criteria For Appraising Highly Specialized Products
NHS England, NICE & Vertex Have ‘Forgotten Patients’ In Orkambi Impasse





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts